

Affinivax



Even though Affinivax was deemed essential as a vaccine lab during the covid-19 pandemic, and construction was allowed to proceed, the virus had an impact on almost every aspect of the project. It was challenging for everyone but with some innovation and much teamwork we pulled it off, and the project is currently on schedule to complete later this year.

Affinivax secured a lease of around 47,000sf at 301 Binney Street, Cambridge, with the intention of building it out to include their company headquarters and an R&D Lab

Hereva Consultants was hired to provide project services from planning through modifications, and into relocation and move-in. We also provided support during operational start-up.

Our project management team developed early stage understanding of the project's needs, and provided scope validation/generation, schedule, high-level budget compilation services and real-time cost management during project delivery. In addition, we worked with their internal team assisting with approval and procurement of external services as needed, such as design and construction team members.

ABOUT OUR CLIENT

Affinivax is a clinical stage biotechnology company with a next generation Multiple Antigen Presentation System (MAPS) vaccine technology platform creating novel vaccines and immunotherapies inducing a broader and more robust immune response.

SPECIFICATIONS	
Client	Affinivax
Project	New Headquarters and Lab Build-Out
Location	301 Binney St. 3rd Floor
SF	~47K
Type	Office/Lab
Time Frame:	2019-2020
Industry	Bio Pharmaceutical
Architect	Tria
Engineers	RGV
CM	TRG
Hereva Team	Juanita Forsythe, Paul Pratt, Dayna Shatraw, Katya Kovbasa